drugset
drugset / Trial / NCT00133393

Pentoxifylline in Children With Malaria

NCT00133393 ↗

Phase 2 Terminated 50 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objectives of this study is to identify a safe, tolerable dose of pentoxifylline in children with cerebral malaria and to establish an acceptable pentoxifylline dosage regimen for use in multi center Phase II and Phase III studies.

Timeline

Start
2002-01
Primary completion
—
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 10 mg/kg —
Subject Pentoxifylline Small molecule 20 mg/kg —
Subject Pentoxifylline Small molecule 30 mg/kg —
Subject Pentoxifylline Small molecule 40 mg/kg —

Indications

Plasmodium falciparum malaria